<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="431">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04579458</url>
  </required_header>
  <id_info>
    <org_study_id>201127</org_study_id>
    <nct_id>NCT04579458</nct_id>
  </id_info>
  <brief_title>Assessment of COVID-19 in Tearfilm</brief_title>
  <official_title>Assessment of COVID (Coronavirus Disease)-19 in Tearfilm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the co-relation of COVID-19 in nasopharyngeal swabs and tears or saliva, and to&#xD;
      determine duration of COVID-19 activity in ocular fluid and saliva by serial tests over 3&#xD;
      months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who underwent COVID-19 testing at VUMC (Vanderbilt University Medical Center) and&#xD;
      had provided a written informed consent to be contacted in the future for COVID related&#xD;
      studies will be offered participation in this study. The COVID- 19 has low prevalence in&#xD;
      ocular fluids (5% of affected patients) but may survive for a long time or replicate in the&#xD;
      conjunctiva, even in asymptomatic patients. Patients with viral conjunctivitis are more&#xD;
      likely to have COVID-19 RNA (ribonucleic acid) in tears. The use of Schirmer's strips to&#xD;
      collect tears for RNA analysis of viruses has been previously validated. VUMC is performing&#xD;
      RNA analysis on nasopharyngeal (NP) swabs for COVID-19 at several locations. Several patients&#xD;
      (test positive and test negative) have given consent to be contacted for future research&#xD;
      purposes and are available in VICTR (Vanderbilt Institute for Clinical and Translational&#xD;
      Research) Datamark and Recovery databases. The positive tested patients will receive a&#xD;
      Schirmer's strip in the mail at their home to place in both eyes to test eye fluid and&#xD;
      receive a tube for saliva while engaging in a zoom session for monitoring of the process.&#xD;
&#xD;
      Methodology: Patients who underwent COVID-19 testing at VUMC and had provided a written&#xD;
      informed consent to be contacted in the future for COVID related studies will be offered&#xD;
      participation in this study. The first test for eye fluid and saliva will occur at home with&#xD;
      remote monitoring. Participants will be mailed a specimen collection kit, engage in a remote&#xD;
      session with a study coordinator through a HIPPA (Health Insurance Portability and&#xD;
      Accountability Act of 1996)-compliant video meeting and collect specimens under supervision&#xD;
      of the study coordinator. Patients will receive a Schirmer's strip to place in both eyes&#xD;
      without topical proparacaine, and a tube to collect saliva. The strips are then sent to the&#xD;
      lab in universal viral transport media. Patients who have positive COVID-19 RNA in tears will&#xD;
      get repeat Schirmer's test every 4 weeks for 3 months- independent of the nasopharyngeal test&#xD;
      results. After a 3-month period, they will be offered a clinic visit at VEI (Vanderbilt Eye&#xD;
      Institute) for full dilated eye exam, fluorescein angiography and aqueous biopsies. Lab&#xD;
      testing for COVID-19 RNA and other ocular inflammatory mediators will be performed by Dr.&#xD;
      Johnathan Schmitz's lab at VUMC under standard viral precautions. All lab analysis will be&#xD;
      performed under a research protocol and not for clinical assessment or reporting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Not able to enroll the amount required.&#xD;
  </why_stopped>
  <start_date type="Actual">December 28, 2020</start_date>
  <completion_date type="Actual">January 22, 2021</completion_date>
  <primary_completion_date type="Actual">January 22, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Co-relation of COVID-19 activity</measure>
    <time_frame>3 months</time_frame>
    <description>Patients will receive a Schirmer's strip to place in both eyes without topical proparacaine, and a tube to collect saliva. The co-relation of COVID-19 in nasopharyngeal swabs and tears or saliva will be measured and reported by serial tests over 3 months.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Covid19</condition>
  <condition>Ophthalmopathy</condition>
  <condition>Eye Diseases</condition>
  <arm_group>
    <arm_group_label>COVID-19 Positive</arm_group_label>
    <description>COVID-19 positive in nasopharyngeal swabs and tears or saliva.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Collection of tears and saliva.</intervention_name>
    <description>Saliva and ocular tears will be collected.</description>
    <arm_group_label>COVID-19 Positive</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who underwent COVID-19 testing at VUMC and tested positive.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who underwent COVID-19 testing at VUMC, tested positive, and had provided a&#xD;
             written informed consent to participate in future COVID related studies will be&#xD;
             offered participation in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under 18.&#xD;
&#xD;
          -  Patients who do not speak Spanish or English&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sapna Gangaputra</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt Eye Institiute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Napoli PE, Nioi M, d'Aloja E, Fossarello M. The Ocular Surface and the Coronavirus Disease 2019: Does a Dual 'Ocular Route' Exist? J Clin Med. 2020 Apr 28;9(5). pii: E1269. doi: 10.3390/jcm9051269.</citation>
    <PMID>32353982</PMID>
  </reference>
  <reference>
    <citation>Xie HT, Jiang SY, Xu KK, Liu X, Xu B, Wang L, Zhang MC. SARS-CoV-2 in the ocular surface of COVID-19 patients. Eye Vis (Lond). 2020 Apr 26;7:23. doi: 10.1186/s40662-020-00189-0. eCollection 2020.</citation>
    <PMID>32355863</PMID>
  </reference>
  <reference>
    <citation>Khavandi S, Tabibzadeh E, Naderan M, Shoar S. Corona virus disease-19 (COVID-19) presenting as conjunctivitis: atypically high-risk during a pandemic. Cont Lens Anterior Eye. 2020 Jun;43(3):211-212. doi: 10.1016/j.clae.2020.04.010. Epub 2020 Apr 27.</citation>
    <PMID>32354654</PMID>
  </reference>
  <reference>
    <citation>Wu P, Duan F, Luo C, Liu Q, Qu X, Liang L, Wu K. Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol. 2020 May 1;138(5):575-578. doi: 10.1001/jamaophthalmol.2020.1291.</citation>
    <PMID>32232433</PMID>
  </reference>
  <reference>
    <citation>Lee SY, Kim MJ, Kim MK, Wee WR. Comparative analysis of polymerase chain reaction assay for herpes simplex virus 1 detection in tear. Korean J Ophthalmol. 2013 Oct;27(5):316-21. doi: 10.3341/kjo.2013.27.5.316. Epub 2013 Sep 10.</citation>
    <PMID>24082768</PMID>
  </reference>
  <reference>
    <citation>WHO. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases - interim guidance. 2020; 2020.</citation>
  </reference>
  <reference>
    <citation>Sullivan PS, Sailey C, Guest JL, Guarner J, Kelley C, Siegler AJ, Valentine-Graves M, Gravens L, Del Rio C, Sanchez TH. Detection of SARS-CoV-2 RNA and Antibodies in Diverse Samples: Protocol to Validate the Sufficiency of Provider-Observed, Home-Collected Blood, Saliva, and Oropharyngeal Samples. JMIR Public Health Surveill. 2020 Apr 24;6(2):e19054. doi: 10.2196/19054.</citation>
    <PMID>32310815</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Sapna Gangaputra</investigator_full_name>
    <investigator_title>Assistant Professor of Ophthalmology Co-Fellowship Director Vitreoretinal Diseases and Surgery</investigator_title>
  </responsible_party>
  <keyword>Positive COVID 19</keyword>
  <keyword>Ophthalmology</keyword>
  <keyword>Eye Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

